CYBB and chronic granulomatous disease: Therefore, these drugs can be used for ROS modulation in NOX2-deficient states, as it has been demonstrated for pioglitazone in gp91phox−/− mice (a CGD model) and ex vivo for primary cells from X-linked CGD patients (74).